Alex Delaney-Gesing 

home

authors

alex-delaney-gesing


John A. Hovanesian, MD, clinical instructor, UCLA Jules Stein Eye Institute, Laguna Hills, CA, discusses the highlights of his presentation titled "The D3 Study: Drug Delivery vs Drops — A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1% in Controlling Post-operative Pain and Inflammation in Patients Undergoing Sequential Cataract Surgery," during the virtual 2020 American Academy of Ophthalmology (AAO) meeting. 

Videos

John A. Hovanesian, MD, discusses the highlights of his presentation on a clinical study evaluating dexamethasone vs prednisolone acetate 1% in controlling postop pain/inflammation in sequential cataract surgery patients.

Controlling postop pain, inflammation in cataract patients: drug delivery vs drops

Biophytis has announced that it will begin recruiting patients in France and Belgium for the second part of the COVA Study analyzing Sarconeos (BIO101), its leading drug candidate, as a potential treatment for acute respiratory failure linked to COVID-19.

Along with Regulatory Authorities in Brazil and the U.S. 

providing authorization for the start of part 2 clinical trials

, authorization has also been obtained in France and Belgium to begin recruitment, according to a 

This follows the completion of enrollment for part 1 of the study, which includes 50 participants.

The COVA Study is a global, multi-center, double-blind, placebo-controlled, two-part phase 2-3 study assessing Sarconeos (BIO101), administered orally, in patients aged 45 and older who have been hospitalized with severe respiratory manifestations of COVID-19, the release stated.

The first part of the study targets preliminary data on the safety, tolerability and activity of Sarconeos (BIO101) in the trial’s participants. Interim analysis is tentatively expected later in this first quarter of this year, pending COVID-19 related delays or pandemic impacts, according to the company.

The second part of the COVA Study includes a phase 3 pivotal randomized study investigating the safety, efficacy of Sarconeos (BIO101) in the respiratory function of 310 COVID-19 patients (including the 50 patients from part 1 of the study), the company states. 

Complete results from both part 1 and part 2 of the study are expected in the second quarter of this year, pending any COVID-19-related delays, patient enrollment issues, or other interruptions.

Articles

Biophytis will begin recruiting patients in France and Belgium for the second part of the COVA Study analyzing its leading drug candidate as a potential treatment for acute respiratory failure linked to COVID-19.

Biophytis expands patient recruitment for part II of COVA Study in France, Belgium

Michael R. Robinson, MD, vice president, Global Therapeutic Area Head, Ophthalmology at Allergan, an AbbVie company, discusses the results from a presentation titled, "Two Phase b Study Results for the Development of a Proprietary Formulation for the Treatment of Presbyopia," presented during the virtual AAO 2020 meeting.

Michael R. Robinson, MD, Allergan, discusses the results from a study analyzing an investigational ophthalmic solution for treatment of symptoms associated with presbyopia presented during the virtual AAO 2020 meeting.

Analysis of an investigational ophthalmic solution for treating presbyopia-related symptoms

Tanner Ferguson, MD, an ophthalmology resident at the Cleveland Clinic's Cole Eye Institute, discusses findings from the study "Trabecular Micro-bypass Stent Implantation (iStent)" + Phacoemulsification in PXG: Six-Year Outcomes," during the virtual AAO 2020 meeting. 


Tanner Ferguson, MD, Cole Eye Institute, discusses findings from the study "Trabecular Micro-bypass Stent Implantation (iStent)" + Phacoemulsification in PXG: Six-Year Outcomes," during the virtual AAO 2020 meeting. 

Author | Alex Delaney-Gesing

Articles

Biophytis expands patient recruitment for part II of COVA Study in France, Belgium

Analysis of an investigational ophthalmic solution for treating presbyopia-related symptoms

Evaluating long-term safety for micro-bypass implant + phaco in PXG

Controlling postop pain, inflammation in cataract patients: drug delivery vs drops